| Budget Amount *help |
¥5,460,000 (Direct Cost: ¥4,200,000、Indirect Cost: ¥1,260,000)
Fiscal Year 2014: ¥1,170,000 (Direct Cost: ¥900,000、Indirect Cost: ¥270,000)
Fiscal Year 2013: ¥1,820,000 (Direct Cost: ¥1,400,000、Indirect Cost: ¥420,000)
Fiscal Year 2012: ¥2,470,000 (Direct Cost: ¥1,900,000、Indirect Cost: ¥570,000)
|
|---|
| Outline of Final Research Achievements |
We developed cerebral ischemia and reperfusion injury model using primate animal. In this model, we demonstrated that Anti-HMGM1 monoclonal antibody (mAb) is able to effectively inhibit the development of brain edema in the ischemic region. This edema inhibitory effect is most likely achieved through the protection of the blood brain barrier (BBB) structure in the ischemic region. We also found that HMGB1 was transported from nuclear to the extracellular space likely due to ischemic vascular lesion, and probably transported to the cell organelles as well. The results suggest that the brain tissue protection effect of HMGB1 mAb may be due to its ability to block HMGB1 nuclear-cytoplasmic translocation in the early reperfusion phase following the focal ischemia in the brain tissue.
|
